Bio-Techne Discounted Cash Flow

The latest DCF fair value for TECH is $23. Investors often review this figure alongside Bio-Techne's historical trend and sector peers before judging valuation or financial health.

A DCF fair value of $23 for Bio-Techne suggests the stock may be overvalued by roughly 68.7% at today's price. That does not mean the market is 'wrong'; it means the model's cash-flow assumptions imply a different intrinsic value. Stress-test the estimate by comparing it with historical valuation ranges and peer multiples.

After noting TECH's DCF fair value ($23), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bio-Techne's DCF fair value against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.